TScan Therapeutics announced layoffs of 104 employees on September 2, 2026. The Waltham biotech cut 75% of staff and paused its Phase 3 ALLOHA-2 hematology trial to put everything behind an in vivo solid tumor program. The chief financial officer and chief medical officer both left the same day.